iRhythm Technologies and Lucem Health have partnered to launch a predictive AI solution to transform the early detection of arrhythmias in patients with comorbid conditions.
The collaboration aims to close the gap in timely diagnosis for millions of undiagnosed patients, using AI to enhance early intervention and patient care.
It combines Lucem Health’s Reveal AI platform with iRhythm’s diagnostic services to early identify risks, enable cardiac monitoring and improve outcomes for high-risk populations.
Also, the strategic partnership enables scalable, data-driven strategies for health systems focused on value-based care.
iRhythm president and CEO Quentin Blackford said: “Healthcare is entering an era where the goal is no longer just to detect disease, but to predict it.
“Together with Lucem Health, iRhythm is helping lead a new way forward in care, with the goal of reaching patients before symptoms surface and before complications arise.
“This is a bold step toward predictive, preventive, and precise care powered by AI, informed by data, and designed for scale. We believe more than 27 million people in the US alone could benefit from proactive cardiac monitoring1 — and this is just the beginning.”
The first commercial offering from the collaboration is an AI-powered solution that analyses clinical and electronic health record data.
It targets people with Type 2 diabetes, chronic kidney disease, chronic obstructive pulmonary disease (COPD), and coronary artery disease, who are at risk of arrhythmias.
Once identified, patients can be monitored using iRhythm’s Zio ECG monitors, which provide continuous heart rhythm monitoring for up to 14 days.
The service, powered by an FDA-approved AI algorithm, delivers actionable insights, helping clinicians make accurate diagnoses and ensuring timely care.
Initial pilot testing by iRhythm and Lucem Health has shown promising results in targeting patient populations with elevated arrhythmia risk.
The AI-powered tool is expected to significantly increase arrhythmia detection, potentially reducing healthcare costs and improving outcomes.
The solution aims to reduce unnecessary healthcare utilisation and improve outcomes for patients with elevated arrhythmia risk.
Lucem Health founder and CEO Sean Cassidy said: “Each day, clinicians find themselves reacting to the circumstances of the patients in their exam rooms, they often don’t have the time or the information they need to deliver truly proactive care.
“Together with iRhythm, we’re bringing predictive intelligence to healthcare’s front lines — enabling earlier action, smarter resource allocation, and better outcomes for patients.”
